The evidence leans constructive9 supporting, 1 against, 0 worth knowing
Supporting
trading 96% above its 200-day average
sitting at 97% of its 52-week range, with little overhead supply from trapped buyers
up 130% over twelve months
matches profit that turns into cash, which has beaten the market by +2.73 points over 20 sessions across 9,184 past signals
11 of the scans it matches have a positive measured record
6 independent kinds of evidence agree today, which is uncommon
revenue grew 59% year on year in the quarter ending 30 June 2026
net margin has widened from 10.0% to 21.7% across four quarters
priced at 0× earnings against an industry median of 45× — 100% below its peers
Against
2 of the scans it matches have historically underperformed the market
Worth knowing
nothing the data supports either way
What would change this read: a close below 479, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working7
Net profit rose 462.4% year on year, from Rs 18 cr to Rs 101 cr.
+462.4%Rs 18 crRs 101 cr
Profit grew faster than revenue, +462.4% against +35.5%.
+462.4%+35.5%
Net margin improved from 5.2% to 21.7%.
5.2%21.7%
Trading 96.4% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+96.4%
Within 2.5% of its 52-week high.
-2.5%
Up 129.7% over the past year.
+129.7%
4 different kinds of evidence point at it tonight, not 4 versions of the same one.
4 families
Needs watching1
A warning rule fires on it tonight: stretched far above trend.
Stretched far above trend
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 3 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
14 of 47 matched on 10 Sep
SHILPAMED matches 14 of the 47 scans today, across 6 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
500 sessions since 26 September 2024
0×
median 0×
0×
now 0×
SHILPAMED trades at 0× trailing earnings, below its median of 0× over this window — 16% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · Dividend filings were typically +0.16pt vs the market over the next 5 sessions (n=940) · AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 59% against the same quarter a year earlier
profit rose 617% year on year
revenue rose in 3 of the last 4 quarters
Going against it
net margin narrowed from 24.7% to 21.7%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
466
92
101
5.16
21.7%
Q4 FY26
31 Mar · consolidated
437
120
108
5.51
24.7%
Q3 FY26
31 Dec · consolidated
410
61
45
2.36
10.9%
Q3 FY25
31 Dec · consolidated
319
41
32
3.25
10.0%
Q2 FY25
30 Sep · consolidated
344
37
18
1.83
5.2%
Q1 FY25
30 Jun · consolidated
293
32
14
1.46
4.8%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+25.6%
Versus 200-day average+96.4%
Below 52-week high-2.5%
Above 52-week low+252.0%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)68.6
Higher closes in last 53 of 5
Six-month return+189.56%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)4.59%
Volume versus 20-day0.5x
Median daily turnoverRs 85.2 cr
Peers
Healthcare · 68 classified companies
SHILPAMED trades at 0.0× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — cheaper than them, by 100%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
10 Sep
1
MACD just turned negative
2 Sep
1
Closed at the very top of its range
31 Aug
4
The market's strongest stocks, Made a new 52-week high today, Above the 200-day EMA, Improving business in an uptrend
28 Aug
3
The market's strongest stocks, Beating the market for 6 months, Inside bar — quieter than yesterday
27 Aug
4
The market's strongest stocks, Beating the market for 6 months, Made a new 52-week high today, Improving business in an uptrend